UTHR
United Therapeutics Corporation
Stock
$541.70−29.68 (−5.19%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.7B | $1.6B | $1.3B | $978M | $803M | $598M | $756M | −$207M | $778M | $474M | $644M | $383M | $355M | $425M | $324M | $250M | $212M | $100M | −$40M |
| Capital expenditures | $592M | $521M | $247M | $230M | $139M | $121M | $59M | $84M | $184M | $86M | $38M | $50M | $47M | $32M | $112M | $36M | $19M | $95M | $124M |
| Free cash flow | $1.1B | $1.0B | $1.1B | $748M | $664M | $477M | $696M | −$290M | $594M | $388M | $606M | $333M | $308M | $393M | $212M | $214M | $193M | $4.3M | −$165M |
| Stock-based compensation | $155M | $148M | $144M | $39M | $107M | $139M | $164M | $45M | −$26M | $74M | $12M | $280M | $190M | $321M | $30M | −$16M | $114M | $101M | $29M |
| Buybacks | $2.5B | $1.0B | $1.0B | $0 | $0 | — | — | — | — | $250M | $500M | $395M | $483M | $42M | $188M | $212M | — | — | — |
| Free cash flow margin | 34.6% | 32.7% | 37.6% | 32.1% | 34.3% | 28.3% | 46.9% | −20.0% | 36.5% | 22.5% | 37.9% | 22.7% | 23.9% | 35.2% | 23.1% | 28.8% | 32.5% | 1.2% | −58.6% |